Weekly Life Science News Round Up: 11th – 15th April
A round-up of the latest news from the Life Science industry; including Clinical Research, Drug Development, Drug Discovery, Diagnostics, Biotechnology and more news from 11th – 15th April 2022.
Versant Ventures announces the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies.
Autigen announces today that it has signed a research collaboration and license agreement with Boehringer Ingelheim to discover, develop, and commercialize transformative therapies for patients with SNHL.
Venomtech is collaborating with Charles River Laboratories to help drug developers explore venom-derived compounds for a wide range of therapeutic targets.
EdiGene has entered into a research collaboration with Peking University Cancer Hospital to understand gene mutation frequency and clinicopathologic features of patients with advanced colorectal cancer in China.
Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announces clinical manufacturing expansion in the UK and the US
CliniSys announces it has acquired ApolloLIMS, a leading provider of laboratory information management systems based in Nashville, Tennessee, and with specialist expertise in clinical, public health, toxicology and molecular diagnostics.
Chimeron Bio announces it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB) to advance the company’s Oncology portfolio to the clinic.
Etcembly has agreed a partnership with leading Norwegian firm Zelluna to engineer T-cell receptors (TCRs) from Zelluna’s pipeline against an undisclosed cancer target.
InfanDx AG announces that it has set up US operations to gain access to the US market for its HypoxE® test.
Engitix enters into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.
Biognosys announce a global strategic partnership agreement with NeoGenomics, a leading provider of oncology testing and global contract research services.
Alzamend Neuro announce that is has contracted with Atlasciences Clinical Kansas and iResearch Atlanta, LLC to manage and conduct, respectively, its Phase IIA multiple ascending dose (“MAD”) study in patients with mild to moderate Alzheimer’s Disease.
Scailyte and Sirona DX announce a strategic partnership to accelerate the development of Advanced Therapies.
Abzena announces the opening of a new Biologics Testing Laboratory situated in close proximity to Abzena’s Biologics process development and manufacturing hub in San Diego, California.
CureVac and GSK announce that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany.